Advertisement
UK markets close in 2 hours 21 minutes

  • FTSE 100

    8,311.47
    +97.98 (+1.19%)
     

  • FTSE 250

    20,419.30
    +254.76 (+1.26%)
     

  • AIM

    777.60
    +6.07 (+0.79%)
     

  • GBP/EUR

    1.1648
    -0.0011 (-0.10%)
     

  • GBP/USD

    1.2557
    -0.0006 (-0.05%)
     

  • Bitcoin GBP

    50,677.87
    +13.52 (+0.03%)
     

  • CMC Crypto 200

    1,320.37
    -44.76 (-3.28%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CRUDE OIL

    77.97
    -0.51 (-0.65%)
     

  • GOLD FUTURES

    2,325.10
    -6.10 (-0.26%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • DAX

    18,307.03
    +131.82 (+0.73%)
     

  • CAC 40

    8,029.88
    +33.24 (+0.42%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Bavarian Nordic (BVNRY) Soars 7.1%: Is Further Upside Left in the Stock?

Zacks Equity Research
·2-min read

Bavarian Nordic (BVNRY) shares ended the last trading session 7.1% higher at $11.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.9% gain over the past four weeks.

Share price rose after the company announced that it has signed multiple contracts with different countries for the supply of its monkeypox vaccine. Based on these supply contracts, the company has upgraded its financial guidance for 2022.

This company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of -23.1%. Revenues are expected to be $74.87 million, up 24.9% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

ADVERTISEMENT

For Bavarian Nordic, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BVNRY going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Bavarian Nordic belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Codiak BioSciences, Inc. (CDAK), closed the last trading session 1.4% lower at $2.78. Over the past month, CDAK has returned -0.4%.

For Codiak BioSciences, Inc. , the consensus EPS estimate for the upcoming report has changed +1.1% over the past month to -$0.78. This represents a change of +21.2% from what the company reported a year ago. Codiak BioSciences, Inc. currently has a Zacks Rank of #3 (Hold).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bavarian Nordic (BVNRY) : Free Stock Analysis Report
 
Codiak BioSciences, Inc. (CDAK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.